Journal of Blood & Lymph

Dr, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States

Publications

• Commentary   
  Tackling the Last Major Obstacle to Cure in Acute Promyelocytic Leukemia
  Author(s): Martin S. Tallman*
  
  Acute Promyelocytic Leukemia (APL) has become the most curable subtype of acute myeloid leukemia in adults with the advent of the differentiating agents, all-trans retinoic acid and arsenic trioxide. However, Early Death (ED) remains a challenge and represents the last major obstacle to the cure of almost every patient. An overwhelming majority of ED in APL is attributable to life-threatening bleeding, a phenomenon driven by complex alterations in the coagulation system. Therefore, prompt recognition of APL and immediate initiation of All-Trans Retinoic Acid (ATRA) in emergency departments–prior to confirmation of the diagnosis–is essential. All-trans retinoic acid must be immediately available, which is often problematic since most institutions will see very few APL patients in a year and will not find it cost-effective to maintain a supply. Aggressive management of the c.. Read More»
  DOI: 10.37421/2165-7831.2024.14.315

  Abstract HTML PDF